The protein p16^INK4A or p16, encoded by the cyclin-dependent kinase (CDK) inhibitor 2A gene, has a critical role in the regulation of the cell cycle by inhibiting CDK4 and CDK6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. Dysregulation of p16^INK4A is frequently observed in numerous types of cancer, including OSCC (29).

HPV expresses the oncoproteins E6 and E7, which deactivate tumour suppressor proteins. The E6 protein induces the degradation of P53, whose function is to halt cell division at the G1 level and induce apoptosis through ubiquitin-mediated proteolysis, inactivating its activity (30–33). Cells expressing E6 are unable to respond to DNA damage signaling mediated by P53 and are thus susceptible to genomic instability. The E7 protein binds and inactivates the retinoblastoma tumour suppressor gene product (pRB), causing the cell to enter S phase, leading to cell cycle disruption, proliferation and malignant transformation. Inactivation of pRB leads to upregulation of p16^INK4a as a cellular response to uncontrolled cell cycle progression (30).

Its importance as a prognostic marker is related to HPV infection. The prevalence of HPV in patients with OSCC has been examined in various research studies. According to Vergori et al (30), HIV-positive individuals are more likely to harbour HPV in the oral cavity than HIV-negative individuals.

A relevant study on an HIV-infected population have indicated an overall prevalence of HPV DNA in the oral cavity ranging from 20 to 45%, with the oncogenic type HPV16 found in 12 to 26% of cases (31). A study by Castro and Filho (32) found that HPV is an independent risk factor for OSCC. The prevalence of HPV in oral cancer, particularly SCC, was observed to be higher for HPV16 (32). One of the most significant studies regarding the relevance of p16 in OSCC is a meta-analysis of 31 studies including ~5,000 patients conducted by Katirachi et al (33). The overall prevalence of HPV+ OSCC in this meta-analysis was ~6% (95% CI; 3–10%), and only one study identified a significant correlation between HPV and OSCC (33).

From a morphological perspective, it has been observed that HPV+ OSCC originates more frequently in the tonsillar crypts and presents more often in advanced stages (III or IV) than HPV-OSCC. On the other hand, the prognostic utility of p16 in OSCC differs among studies given its low prevalence, although according to studies such as that by Doll et al (34), P16 expression is connected to a better survival rate in individuals undergoing primary surgery with adjuvant radio(chemo)therapy (34). However, meta-analyses such as that of Christianto et al (35), which evaluated 22 articles comprising 3,065 patients with OSCC, observed that HPV-positive OSCC is associated with significantly decreased survival.

Therefore, dysregulation of p16^INK4A is associated with various types of malignancies, including OSCC, where its importance is directly associated with HPV infection. As mentioned above, several studies have examined the prevalence of HPV in OSCC and found considerably high rates of p16 positivity. While certain reports suggest better outcomes for patients with P16-expressing OSCC undergoing specific therapies, meta-analyses offer a more nuanced perspective and indicate decreased outcomes in HPV-positive cases. This intricate interplay underscores the need for specialized research and approaches. Understanding these processes has the potential to offer more effective defences against OSCC, reflecting the evolving nature of cancer treatment.

PD-L1, also known as CD274 or B7-H1, is a protein that has an important role in oncology, particularly in the context of immunotherapy. In OSCC, the role of PD-L1 is increasingly recognized as crucial, not only in terms of understanding tumour biology but also for determining prognosis and establishing therapeutic strategies. PD-L1 is typically expressed on the surface of certain cells, including cancer cells, where it interacts with its receptor, PD-1, found on T cells (36). This interaction inhibits the immune response and allows cancer cells to evade the immune system. This mechanism of immune evasion is particularly important in OSCC, as there is growing evidence that PD-L1 expression is associated with more aggressive disease features, such as advanced tumour stage, nodal metastases and unfavourable overall survival. In recent years, immune checkpoint inhibitors that block this interaction have shown promising results in various cancer types, including OSCC (37,38). This is because PD-L1 expression appears to be regulated by multiple signalling pathways, including MAPK, PI3K and Akt/PKB, which are commonly altered in head and neck carcinoma. As a consequence of these molecular interactions, it is a dynamic biomarker that is subject to variations (39).

In the last decade, several immune checkpoint inhibitors targeting PD-1 or PD-L1 have been approved for the treatment of recurrent or metastatic OSCC. Among these drugs are pembrolizumab and nivolumab (targeting PD-1) and atezolizumab and durvalumab (targeting PD-L1). These inhibitors have shown promising results in terms of response rates and survival, particularly in patients with PD-L1-positive tumours, changing the treatment paradigm for this patient population. For instance, pembrolizumab was approved as a first-line treatment for relapsed or metastatic OSCC with a PD-L1 combined positive score of 1 or higher according to the KEYNOTE-048 trial (40,41). This study demonstrated that pembrolizumab improved overall survival compared to that with the standard therapy EXTREME (cetuximab with platinum-based chemotherapy) (42).

Therefore, PD-L1+ tumours tend to exhibit better response rates to anti-PD-1/PD-L1 therapies compared to PD-L1-tumours (40). It is important to note that, albeit to a lesser extent, PD-L1-tumours also benefit from these treatments (41), indicating the need to consider additional factors, such as HPV status or tumour mutational burden, when initiating these treatments.

However, studies such as CHECKMATE-141 failed to show a significant association between PD-L1 expression and tumour response or survival when evaluating nivolumab in platinum-resistant patients (42). The lack of concordance in these results obtained from different studies may be explained by the heterogeneity in biomarker expression, as well as the lack of uniformity in assays and the variability in thresholds used to define PD-L1 positivity, leading to the establishment of harmonization projects for PD-L1 assays by the scientific community and regulatory bodies (41,42).

Anti-PD-L1 therapies, such as atezolizumab and durvalumab, are also being studied at various stages of clinical trials for OSCC and are showing promising results. Despite these advances, overall response rates to monotherapies against PD-1/PD-L1 remain relatively modest, underscoring the need for strategies to improve their efficacy (43). The combination of immune checkpoint inhibitors with other therapies, such as cytotoxic chemotherapy, radiotherapy or other immunotherapeutic agents, is a promising approach under active investigation (44).

EGFR is a transmembrane receptor that belongs to the ErbB family of receptor tyrosine kinases. This receptor has a critical role in the pathogenesis and progression of several cancers, including OSCC. EGFR is frequently overexpressed in OSCC and its upregulation is associated with aggressive tumour behaviour, increased invasiveness and poor prognosis (45). In this sense, it correlates with advanced tumour stage, lymph node metastasis and lower overall survival rates. Therefore, the determination of EGFR expression levels in OSCC may serve as a valuable prognostic indicator to aid in treatment planning and patient management (46).

EGFR is not only a prognostic marker but also an emerging therapeutic target in OSCC. Several strategies, including monoclonal antibodies (such as cetuximab) and small molecule tyrosine kinase inhibitors (such as erlotinib), have been developed to inhibit EGFR signalling. Cetuximab has been shown to be clinically effective in combination with radiotherapy or chemotherapy for locally advanced OSCC, leading to improved survival rates. It is important to highlight that in recent years, EGFR therapies have been shown to have the potential to sensitize tumours to other treatments, improve the efficacy of chemotherapy and radiotherapy, and overcome treatment resistance (47). Related to treatment resistance, several molecular alterations, such as EGFR gene amplification, mutations and activation of downstream signalling pathways, remain a major challenge in these patients and represent one of the main limitations of these therapies (48).

EGFR has a critical role in the pathogenesis and progression of OSCC. Its overexpression is associated with aggressive tumour behaviour and poor prognosis. Targeting EGFR represents a promising therapeutic approach for OSCC that may improve treatment outcomes. However, further research is needed to refine patient selection criteria, overcome resistance mechanisms and optimize treatment strategies to fully realize the therapeutic potential of EGFR inhibition in OSCC.

Cyclin D1 is an important regulatory protein involved in cell-cycle progression and has been extensively studied in various cancers, including OSCC. Cyclin D1 has a critical role in regulating the transition from G1 to S phase of the cell cycle by forming complexes with CDKs. Overexpression of cyclin D1 has been observed in OSCC, which is associated with impaired cell cycle control, increased proliferation and tumour progression (49). Multiple molecular alterations, including gene amplifications, mutations and dysregulated signalling pathways, contribute to the upregulation of cyclin D1 in OSCC (50).

Numerous studies have investigated the prognostic significance of cyclin D1 expression in OSCC. Increased expression of cyclin D1 has been associated with unfavourable clinicopathological features, including advanced tumour stage, lymph node metastasis and poor overall survival. Its overexpression serves as an independent prognostic marker for aggressive tumour behaviour and may aid in risk stratification and treatment planning (51–53).

Cyclin D1 is closely involved in the interaction with various oncogenic signalling pathways in OSCC, such as p53, RB and components of the Wnt/β-catenin pathway, thus influencing cell-cycle progression, apoptosis and tumour growth (54). Despite the growing evidence for the link between cyclin D1 and OSCC, several challenges remain to be overcome. These include standardization of cyclin D1 determination methods, identification of predictive biomarkers for treatment response, and understanding the complex network of interactions involving cyclin D1 in OSCC (55,56).

In conclusion, cyclin D1 has a critical role in the pathogenesis of OSCC and serves as a prognostic marker. Its dysregulation contributes to tumour progression and poor clinical outcomes. Further exploration of the molecular mechanisms underlying cyclin D1 involvement in OSCC and clinical validation of therapeutic approaches targeting cyclin D1 will pave the way for more effective treatment strategies and improved outcomes for OSCC.

Ki-67 is a nuclear protein associated with cell proliferation and has been shown to be a valuable biomarker in cancer research, including OSCC. Ki-67 is commonly used as a marker of cell proliferation, as it is present in the active phases of the cell cycle (G1, S, G2 and mitosis) (57). OSCC is characterized by dysregulated cell proliferation and Ki-67 expression levels reflect proliferation activity in the tumour. High Ki-67 expression in OSCC is associated with aggressive clinicopathological features in various cancers, such as breast cancer (58,59).

Numerous studies have investigated the prognostic value of Ki-67 expression in head and neck cancer. Increased Ki-67 expression has been associated with decreased overall survival and disease-free survival, and increased risk of recurrence (60,61). Its evaluation may be helpful in risk stratification, treatment planning and posttreatment surveillance. Ki-67 expression has been shown to be particularly valuable in identifying high-risk subgroups among patients with early-stage OSCC, for whom accurate prognosis prediction is difficult. Ki-67 expression has also been studied as a predictive marker of treatment response in OSCC (62). Low Ki-67 expression has been associated with a better response to therapy, including surgery, radiotherapy and chemotherapy (63). Conversely, high Ki-67 expression may indicate treatment resistance and the need for more aggressive therapeutic approaches. Incorporating Ki-67 assessment into treatment decision-making may help personalize treatment strategies and optimize outcomes (64).

Combining Ki-67 assessment with other molecular biomarkers has the potential to improve risk stratification and treatment planning in OSCC. Integration of Ki-67 with factors such as those previously discussed (PD-L1, cyclin D1, EGFR and p16) may lead to a more comprehensive understanding of tumour behaviour and enable personalized therapeutic approaches (65).

In summary, the evaluation of histologic biomarkers in OSCC, including p16, EGFR, PD-L1, cyclin D1 and Ki-67, provides valuable insight into tumour behaviour, prognosis and response to treatment. These biomarkers have the potential to aid in risk stratification, treatment planning and the development of targeted therapies for OSCC.

CEA is a high-molecular-weight glycoprotein, isolated from a tumour cell extract, and is found in the cytoplasmic membrane of numerous glandular cells. The term carcinoembryonic is due to its presence in foetal colonic mucosa (66). Its physiological function is unknown. Due to its structural similarity with members of the immunoglobulin family, it may be involved in cellular recognition mechanisms or cell adhesion mechanisms.

It is usually present at very low concentrations in human serum, generally below 5 ng/ml. However, of note, higher levels (5–10 ng/ml) may be found in healthy smokers. Initially, CEA was thought to be a specific marker for digestive tract tumours; later studies revealed that it is elevated in various types of tumour, including OSCC (67). It may also be elevated in nontumor diseases, such as renal insufficiency, liver cirrhosis, pancreatitis and inflammatory bowel disease.

Several studies have evaluated the diagnostic value of CEA in OSCC. For instance, a study investigated the diagnostic value of serum tumour markers, including CEA, in patients with OSCC, and the results showed that CEA levels were significantly higher in these patients than in patients with benign oral tumours and healthy controls (68). This suggests that CEA may be a useful biomarker for its detection, as its overexpression in these types of cancer may be related to the malignant transformation of epithelial cells (67). However, due to the variability in CEA levels among patients and the possibility of elevations in other types of diseases, CEA is not used as a sole marker for the diagnosis of head and neck cancer but rather as part of a more comprehensive diagnostic approach (68).

In addition to its diagnostic value, CEA levels may also be useful for monitoring treatment response in patients with head and neck cancer. A decrease in CEA levels during or after treatment may indicate a favourable treatment response (67,68).

Apart from CEA, other tumour markers have also been studied in OSCC. For instance, a study identified serum autoantibodies against sideroflexin 3 as a potential tumour marker for OSCC (67). Furthermore, another study revealed that CEA levels in saliva increase in the presence of oral cavity malignancies, including OSCC (69). These findings suggest that CEA, along with other tumour markers, may be of diagnostic value.

It is important to note that the diagnostic accuracy of CEA and other tumour markers in OSCC may vary depending on the specific marker and the studied population. For instance, the diagnostic accuracy of progastrin-releasing peptide (ProGRP), CEA, cytokeratin 19 fragment antigen (CYFRA 21-1) and neuron-specific enolase in the differential diagnosis of small cell lung cancer demonstrated that ProGRP exhibited higher detection accuracy than CEA in lung cancer (68). Therefore, further research is needed to determine the specific diagnostic value of CEA in OSCC.

VEGF has a crucial role in OSCC by promoting angiogenesis, invasiveness, aggressiveness and proliferation of cancer cells (70). The overexpression of VEGF has been associated with tumour progression, lymph node metastasis and poor prognosis in OSCC (71,72). Several studies have investigated the expression and role of VEGF in OSCC.

The expression of VEGF-A and its receptor VEGFR-2 has been evaluated in patients with OSCC. The results showed that VEGF-A gene expression and serum levels were significantly higher in patients with OSCC than in controls. In addition, VEGFR-2 expression was observed in tumour tissues. These findings suggest that VEGF-A and VEGFR-2 may have a role in the pathophysiology of OSCC (71).

Furthermore, the correlation between clinicopathological factors and VEGF expression in OSCC was examined. Immunohistochemical staining and reverse transcription-quantitative (RT-q)PCR were performed to assess VEGF expression. The results showed that high-level staining of VEGF was observed in poorly differentiated and invasive OSCC. There were significant correlations between VEGF expression and histologic differentiation and tumour size. These findings suggest that VEGF expression may be associated with tumour aggressiveness in OSCC (72).

In addition to its role in angiogenesis, VEGF has been implicated in the epithelial-to-mesenchymal transition (EMT) process in OSCC. Neuropilin-1 (NRP1), a coreceptor of VEGF, has been shown to promote EMT by activating the NF-κB pathway (72). In this sense, NRP1 overexpression promotes EMT in OSCC. Inhibition of the NF-κB pathway reverses the NRP1-mediated EMT process. These findings suggest that VEGF-NRP1 signalling may contribute to the invasive and metastatic potential of OSCC (73).

Furthermore, Alsafadi and Manadili (74) investigated the expression of VEGF in OSCC after inducing it in hamsters and subjecting them to radiotherapy. The results showed that VEGF expression was not significantly different between the group that received radiotherapy and the group that did not. In addition, tumour cells that were resistant to radiotherapy showed positive expression of VEGF. These findings suggest that VEGF expression may be associated with radioresistance in OSCC (74). In conclusion, VEGF has a significant role in the pathogenesis and progression of OSCC. Its overexpression has been associated with tumour aggressiveness, lymph node metastasis and poor prognosis in OSCC.

CA-125 is a glycoprotein initially isolated from ovarian tumours and produced under normal conditions by structures derived from Müller's ducts (fallopian tube, endocervix and vaginal fundus), as well as in the pleural, pericardial and peritoneal mesothelia. Concentrations <35–40 U/ml are considered normal. CA-125 is the marker of choice for epithelial ovarian tumours (except mucinous ovarian tumours), but several studies have investigated the expression of CA-125 in patients with OSCC and its potential as a biomarker with diagnostic, predictive and prognostic utility (75,76).

The serum concentration of CA-125 accurately reflects the malignant degree of the tumour mass, and thus, pretreatment serum values are directly related to the tumour stage in patients (75). However, higher levels of CA-125 may be detected in benign conditions, such as endometriosis, benign ovarian tumours, cysts or tuberculosis.

Saliva has also been investigated as a diagnostic medium to detect biomarkers in patients with OSCC. Zhang et al (75) reported that an increase in CA-125 levels in saliva may be considered a salivary biomarker for cancers of the oral cavity. Similarly, Roi et al (76) found that CA-125 levels were significantly elevated in the saliva of patients with oral cancer. These findings suggest that CA-125 may be a potential salivary biomarker for OSCC (75,76).

Furthermore, Goldoni et al (77) found that CA-125 levels were significantly elevated in saliva samples from patients with OSCC analysed using the immunoblot technique. They also reported that elevated levels of soluble CD44 in saliva were present in the majority of OSCC cases and could distinguish cancer from benign tumours with high specificity (77).

Furthermore, a review mentioned that CA-125 has been studied as a diagnostic marker in head and neck SCC, including OSCC. They emphasized the importance of protein markers, such as CA-125 in the diagnosis and progression of various cancer types (78).

In this context, the available literature suggests that CA-125 may be a potential biomarker for OSCC, but further research is needed to validate its diagnostic and prognostic value in patients with OSCC. Saliva-based diagnostic methods, including the analysis of salivary biomarkers such as CA-125, show promise for the early detection of OSCC.

CYFRA 21-1 is a soluble form of cytokeratin 19, a structural protein found in epithelial cells. Research has been conducted to determine the clinical value of CYFRA 21-1 in the diagnosis, prognosis and follow-up of head and neck cancer.

Rajkumar et al (79) investigated the levels of salivary and serum CYFRA 21-1 in patients with oral precancer and OSCC. The study found that CYFRA 21-1 levels were increased in both salivary and serum samples of patients with OSCC compared to healthy controls (79). This suggests that CYFRA 21-1 may serve as a potential biomarker for the detection of OSCC. In reference to its prognostic utility, Liu et al (80) highlighted that high levels of CYFRA 21-1 were significantly associated with shorter overall survival.

CYFRA 21-1 is not specific to OSCC and has been studied in other types of cancer as well. However, the studies mentioned above provide evidence for the potential utility of CYFRA 21-1 as a biomarker in OSCC.

SCCA is a member of the serine protease inhibitor family located in the serine protease inhibitor (serpin) group on chromosome 18q21.3. It is a glycoprotein with a molecular weight of ~48 kDa, a molecule initially described from cervical tissue. Molecular studies demonstrate that SCCA is transcribed by two nearly identical genes (SCCA1 and SCCA2), and it has been observed that both SCCA1 and SCCA2 are expressed in moderately and well-differentiated tumours. It is thought that SCCA has a role in protecting tissue against enzymatic degradation. However, its exact function remains to be fully elucidated. It has been shown that SCCA2 inhibits chymotrypsin-like proteinases, such as cathepsin G and mast cell chymase, while SCCA1 inhibits cysteine proteinases such as cathepsins K, L and S (81,82).

In terms of its clinical utility, its use as a marker for the diagnosis, prognosis, monitoring and histological differentiation of certain squamous lineage cancers, such as lung SCC, cervical cancer, OSCC and anal cancer, has been explored (81). This is particularly useful, since ~90% of head and neck cancer cases are of a squamous lineage.

Regarding its diagnostic utility, in certain cases, elevated levels of SCCA in the blood may suggest the presence of SCC. Furthermore, the presence of SCCA has been associated with unfavourable prognosis in certain cases, serving as a guide for clinical decision making (82).

This antigen may be physiologically found in saliva, hair and skin particles; thus, there is a certain risk of contamination that may lead to inaccurate SCCA values in current assays. Furthermore, it may be present in other benign conditions and its levels may vary based on the method of blood sample collection for subsequent analysis (83).

In OSCC, SCCA is useful for aiding in the diagnosis in certain cases, as elevated levels of SCCA in the blood may suggest the presence of SCC. In addition, the presence of SCCA has been associated with a poorer prognosis in certain cases. Due to its short half-life, which is <24 h, it may assist in postoperative monitoring; in this way, SCCA levels in the blood generally decrease after tumour resection. It also aids in monitoring the response to a specific therapy, as it may decrease in responsive tumours and increase with recurrence (82,83). The increased SCCA2/SCCA1 mRNA ratio in a primary tumour is also associated with cancer recurrence; hence, it is interesting to detect both SCCA1 and SCCA2 to determine total SCCA expression (82). However, currently available assay systems cannot differentiate between the two isoforms in this manner, as the assays were not developed for this specific purpose (81).

It is worth noting that currently, there is no firm evidence or reports on the interaction between HPV status and SCCA in relation to OSCC prognosis (83).

Research on SCCA remains active, with the aim of better understanding its function, clinical utility and limitations. In addition, more sensitive and specific assay methods for its detection and quantification are being developed and evaluated (82).